Zhang Qiongshuai, Xu Xiaohong, Sun Shaoqian, Cao Fang, Li Jiannan, Qi Xun, Ji Guangcheng, Wang Yufeng, Song Bailin
Department of Acupuncture and Tuina,Changchun University of Chinese Medicine, Changchun.
Graduate school, Changchun University of Chinese Medicine, Changchun.
Medicine (Baltimore). 2020 Jul 10;99(28):e21039. doi: 10.1097/MD.0000000000021039.
Novel coronavirus has infected 4.33 million people in more than 200 countries in the current global outbreak of COVID-19. However, there is still no effective drug to treat the disease, and acupuncture and moxibustion is utilized as adjuvant therapy for the treatment of COVID-19 in China.
Nine electronic databases: PubMed, EMBASE, Cochrane library, Web of Science (WOS), Google Scholar, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database (Wanfang) and 2 clinical trials register platforms: Chinese Clinical Trial Registry (ChiCTR), ClinicalTrials.gov (www.ClinicalTrials.gov/) will be searched for RCTs of A&M for COVID-19. The screening process will be developed by 2 independent reviewers, and meta-analysis will be performed with RevMan (V5.3.5) software.
The study results will be contributed to a scientific journal after peer-reviewed for publication.
The study will provide up-to-date evidence of the effectiveness and safety of A&M for patients with COVID-19.
CRD42020185776.
在当前全球新冠疫情中，新型冠状病毒已在200多个国家感染了433万人。然而，目前仍没有有效的药物来治疗该疾病，在中国，针灸被用作治疗新冠肺炎的辅助疗法。
将检索九个电子数据库：PubMed、EMBASE、Cochrane图书馆、科学引文索引（WOS）、谷歌学术、中国知网（CNKI）、中国生物医学文献数据库（CBM）、中文科技期刊数据库（VIP）、万方数据库（万方），以及两个临床试验注册平台：中国临床试验注册中心（ChiCTR）、美国国立医学图书馆临床试验数据库（ClinicalTrials.gov），以查找针灸治疗新冠肺炎的随机对照试验。筛选过程将由两名独立评审员进行，荟萃分析将使用RevMan（V5.3.5）软件进行。
研究结果将在经过同行评审后发表在科学期刊上。
本研究将为针灸治疗新冠肺炎患者的有效性和安全性提供最新证据。
国际前瞻性注册系统（PROSPERO）注册号：CRD42020185776。
